TREATMENT OF NEURODEGENERATIVE DISEASES

• Main Authors: GUERREIRO DA SILVA, Serge, MICHEL, Patrick Pierre
• Format: Patent
• Language: English; French
• Published: 24.05.2018
• Subjects: GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS; TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE; TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINSTCLIMATE CHANGE

The present invention relates to an agonist of the receptor of 1-[(2R,3R,4S,5R)-5-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid, preferably an agonist of two- pore channel 1 (TPC1) and/or two-pore channel 2 (TPC2), for the treatment and/or prevention of neurodegenerative disorders. La présente invention concerne un agoniste du récepteur de l'acide 1-[(2R,3R,4S,5R)-5-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]méthoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxyméthyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylique, de préférence un agoniste de canal à deux pores 1 (TPC1) et/ou de canal à deux pores 2 (TPC2), pour le traitement et/ou la prévention de troubles neurodégénératifs.